GMAB vs. VTRS: Genmab vs. Viatris Stock Comparison

Company Profile

Genmab (GMAB) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Viatris (VTRS) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Genmab (GMAB) reports 12.07%, ranking against industry peers normally.

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Genmab (GMAB) reports 16.97%, ranking against industry peers normally.

Genmab (GMAB) at 37.15% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

Profitability Metrics

Growth

Genmab (GMAB) at 19.19% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Genmab (GMAB) reports EPS growth of -9.23%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Genmab (GMAB) at 2.45 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Genmab (GMAB) at 0.82 and Viatris (VTRS) at 0.99 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Genmab (GMAB) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Genmab (GMAB) trades at 45.84 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Genmab (GMAB) at 7.68 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Genmab (GMAB) at 5.36 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics